Sustained-release deslorelin acetate implants disrupt oestrous cyclicity in the mare

There is a need for a safe, effective and practical method of oestrus suppression in the mare. The aim of this study was to monitor ovarian activity in mares exposed to either 9.4 or 28.2 mg deslorelin acetate, a GnRH agonist, in the form of a sustained-release implant. Following oestrus synchronisation, mares were randomly assigned to one of three groups (n = 4 per group) and administered either one (Des1 group; 9.4 mg) or three (Des3 group; 28.2 mg) implants of deslorelin acetate (Suprelorin-12, Virbac Australia) or one blank implant (Control group; Virbac Australia). Mares underwent weekly blood sampling for 12 weeks following implant placement (Day 0–Day 84), with transrectal palpation and ultrasonography of the reproductive tract at all sampling timepoints except Days 56, 70 and 77. All mares showed baseline serum progesterone concentrations (SPC; ≤1.3 nmol/L or 0.4 ng/ml) on Day 0. Cycling Control mares showed typical oestrous cyclicity characterised by peaks and troughs in SPC over time. Four of eight treated mares demonstrated a sustained elevation in SPC after the initial ovulation after implant placement; SPC declined to baseline levels (Des1 group; 2 mares) or remained elevated (Des3 group; 2 mares) at the final sampling timepoint on Day 84. Oestrous cyclicity was erratic in three of the remaining four treated mares. In total, 87.5% (7 of 8) of treated mares showed atypical oestrous cyclicity after implant placement. These results suggest that deslorelin acetate disrupts oestrous cyclicity in the mare, which warrants further research.     

A comparative efficacy test of 1 versus 2 doses of CIRCOQ PCV2 subunit vaccine against naturally occurring PCV2-type d in piglets with high maternally derived antibodies (MDAs) on a Vietnamese swine farm

The aim of this study was to evaluate the protective efficacy of the CIRCOQ porcine circovirus type 2 (PCV2) subunit vaccine in piglets with high maternally derived antibodies (MDAs) against disease caused by natural infection with PCV2d. A total of 130 weaned, 21-day-old healthy pigs was allocated into 3 trial groups. The signs of respiratory disorder were higher in unvaccinated pigs than in vaccinated pigs at 13 to 17 weeks old (P < 0.05), 18 to 22 weeks old (P < 0.001), and 23 to 27 weeks old (P < 0.01). The unvaccinated pigs had an early rate of dermatitis at 8 to 12 weeks old (10.0%), 13 to 17 weeks old (30.0%), 18 to 22 weeks old (46.7%), and 23 to 27 weeks old (33.3%), while there were no cases of dermatitis in vaccinated pigs. There was a significant difference (P < 0.05) in the mortality of pigs in the unvaccinated group and the 2-dosed vaccinated group. PCV2 viremia was detected in the blood and peaked at 105 days old in both unvaccinated pigs (Ct-adj = 8.40) and pigs vaccinated with 1 dose (Ct-adj = 6.37), while no detectable PCV2 virus was found in the blood of pigs vaccinated with 2 doses. At 77 and 105 days old, the PCV2 viremia load (Ct-adj) of unvaccinated pigs and those vaccinated with 1 dose was significantly higher (P < 0.05) than that of the 2-dosed vaccinated pigs. The body weight (BW), average weight gain (AWG), and average daily gain (ADG) in both groups of vaccinated pigs were significantly higher (P < 0.05) than those of unvaccinated pigs. The study vaccine was significantly efficacious in protecting vaccinated pigs against clinical symptoms, blood viral load, and mortality, as well as improving productivity, compared with unvaccinated pigs.     

Influence of postruminal supplementation of methionine and lysine, isoleucine, or all three amino acids on intake and chewing behavior, ruminal fermentation, and milk and milk component production.

Four multiparous Holstein cows were fed a basal diet balanced with the Cornell Net Protein and Carbohydrate System (CNCPS). Diets were formulated to be co-limiting in intestinally absorbable supplies of methionine, lysine, and isoleucine. Cows were supplemented with no amino acids (control); lysine and methionine in a ruminally protected form; isoleucine by abomasal infusion; or lysine, methionine, and isoleucine in a 4x4 Latin square arrangement of treatments with 28-d periods. Performance of cows on all treatments was lower than expected due to low intake of DM that could have been caused by the high fiber level of the basal diet. This high fiber level was likely responsible for the high daily chewing times for cows fed all diets, which was consistent with the high ruminal pH values. Intake of DM and its components were not influenced by any treatment. Milk protein percentage tended to be higher when cows were fed diets supplemented with ruminally protected lysine and methionine; however, production of milk, milk fat, and milk lactose were not affected by any treatment. Cows tended to have a higher milk lactose proportion and tended to produce more milk and milk lactose when they were abomasally infused with isoleucine alone. However, when cows were supplemented with all three amino acids, milk production and composition did not differ from that of cows fed the unsupplemented diet. Use of the CNCPS to evaluate the performance of the cows fed the unsupplemented diet suggested that these cows may have been colimited by intestinally absorbable supplies of lysine, isoleucine, and methionine in addition to metabolizable protein. Evaluation of the unsupplemented diet with an alternate model, Shield, suggested that cows fed the unsupplemented diet may have been colimited by intestinally absorbable supplies of lysine, isoleucine, and arginine. Results suggest that enhanced delivery of intestinally absorbable isoleucine may stimulate milk lactose synthesis.